RVMD Revolution Medicines, Inc.

Healthcare · Biotechnology

Momentum 10.0 · Strong

205.15

+3.71%

About the company

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Website

—

44.0B

—

-8.87

116.12

52-week range

205

low 34.1 high 206

Dividend deep dive

Revolution Medicines, Inc. (RVMD) operates in the Biotechnology industry within the Healthcare sector. The company currently does not pay a dividend, so there is no dividend yield, dividend rating, or a 5-year yield band to report. The intrinsic momentum and value scores, which gauge price trend and valuation, are not provided in the available data for this equity.

Dividend history

Revolution Medicines, Inc. has not established a dividend policy and does not distribute regular dividends to shareholders. Consequently, there is no dividend payment history, a streak of dividend increases, or compound annual growth rate (CAGR) figures (3-year or 5-year) to report for this company. As such, investors seeking income from dividends will not find it with this equity at present, as no dividend payments or related growth metrics are recorded.

Dividend safety

As Revolution Medicines, Inc. does not currently pay a dividend, traditional dividend safety metrics such as payout ratio or FFO payout percentage are not applicable.

Quantic · Free

Read the rest of the safety verdict

Plus the key risks and what to watch next — free, no card.

Try a sample portfolio Sign up free

AI-generated from Quantic's dividend data · Updated 19 Jul 2026 · Information, not financial advice.